Moderna (MRNA)
(Delayed Data from NSDQ)
$82.44 USD
+1.40 (1.73%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $82.34 -0.10 (-0.12%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$82.44 USD
+1.40 (1.73%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $82.34 -0.10 (-0.12%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
Moderna (MRNA) Stock Moves -0.93%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $123.98, moving -0.93% from the previous trading session.
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
by Kinjel Shah
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?
by Kinjel Shah
Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
Should Direxion NASDAQ-100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQE
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Moderna (MRNA) reachead $116.07 at the closing of the latest trading day, reflecting a -0.33% change compared to its last close.
Play Likely Earnings Beat With 5 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Chewy (CHWY), Wingstop (WING), Moderna (MRNA), Tenet Healthcare (THC) and Kinross Gold (KGC) are likely to beat on the bottom line in their upcoming releases.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
by Zacks Equity Research
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.
CDC Narrows Age Recommendation for Use of RSV Vaccine
by Zacks Equity Research
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
by Zacks Equity Research
Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
by Kinjel Shah
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Moderna (MRNA) closed at $137.60 in the latest trading session, marking a +0.44% move from the prior day.
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
by Zacks Equity Research
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QQEW
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Moderna (MRNA) concluded the recent trading session at $137.90, signifying a -1.52% move from its prior day's close.
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $148.59, marking a -1.6% move from the previous day.